From Nasdaq: 2025-04-19 16:05:00

President Trump’s tariffs have created uncertainty in the pharmaceutical industry, even though they haven’t been directly impacted yet. Eli Lilly, a leading pharma stock, could face challenges with rising raw material costs and supply chain disruptions if tariffs are imposed. Despite short-term concerns, Lilly’s long-term prospects look bright with blockbuster drugs and opportunities in weight loss, cancer, and Alzheimer’s treatments. Investors should consider dollar-cost averaging and a long-term mindset when buying Lilly stock, as the company’s diversified portfolio offers potential for growth.

Although tariffs could affect Lilly’s financials in the short term, the company’s long-term outlook remains positive due to its diverse product portfolio and billion-dollar opportunities in different areas of the pharmaceutical market. Consider investing in Lilly with a focus on long-term growth, as the company continues to innovate and expand its offerings in different therapeutic areas.



Read more at Nasdaq: Is Eli Lilly Stock a Buy Right Now?